What question did this study set out to answer?

The study aims to investigate how TMEPAI influences paclitaxel resistance in triple-negative breast cancer cells.

February 11, 2026Open Access

TMEPAI Confers Paclitaxel Resistance in Triple-Negative Breast Cancer Cells by Promoting AKT Phosphorylation and Its Downstream Cascade

Puntos clave

The study aims to investigate how TMEPAI influences paclitaxel resistance in triple-negative breast cancer cells.
In vitro experiments conducted on triple-negative breast cancer cell lines
Assessment of TMEPAI levels in relation to paclitaxel response
Measurement of AKT phosphorylation and apoptosis rates
TMEPAI levels correlate with increased paclitaxel resistance
Enhanced AKT phosphorylation observed in resistant cells
Reduction in apoptosis and increased drug efflux noted in cells with higher TMEPAI levels

Resumen

TMEPAI appears to facilitate paclitaxel resistance in triple-negative breast cancer cells by promoting cell survival signaling, inhibiting apoptosis, enhancing drug efflux, and initiating epithelial-mesenchymal transition (EMT). Targeting TMEPAI may be a viable approach to overcoming resistance and improving treatment outcomes in triple-negative breast cancer cells.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Louisa et al. (Sun,) studied this question.

synapsesocial.com/papers/698c1c53267fb587c655eb09 https://doi.org/https://doi.org/10.31557/apjcp.2026.27.2.547

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo